Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); Selincro for the treatment of alcohol dependence; and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS product for the treatment of acute migrain; rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.
IPO Year: 2006
Exchange: NASDAQ
Website: acorda.com
4 - Acorda Therapeutics, Inc. (0001008848) (Issuer)
3 - Acorda Therapeutics, Inc. (0001008848) (Issuer)
4 - Acorda Therapeutics, Inc. (0001008848) (Issuer)
4 - Acorda Therapeutics, Inc. (0001008848) (Issuer)
4 - Acorda Therapeutics, Inc. (0001008848) (Issuer)
4 - Acorda Therapeutics, Inc. (0001008848) (Issuer)
4 - Acorda Therapeutics, Inc. (0001008848) (Issuer)
4 - Acorda Therapeutics, Inc. (0001008848) (Issuer)
4 - Acorda Therapeutics, Inc. (0001008848) (Issuer)
4 - Acorda Therapeutics, Inc. (0001008848) (Issuer)
HC Wainwright & Co. upgraded Acorda Therapeutics from Neutral to Buy and set a new price target of $10.00 from $5.00 previously
Acorda Therapeutics, Inc. (NASDAQ:ACOR) today announced that it will no longer hold its fourth quarter and year end 2023 earnings conference call originally scheduled for Monday, April 1 at 4:30 p.m. ET. The Company does expect to timely file its Annual Report on Form 10-K for the period ended December 31, 2023. About Acorda Therapeutics Acorda Therapeutics develops therapies to restore function and improve the lives of people with neurological disorders. INBRIJA® is approved for intermittent treatment of OFF episodes in adults with Parkinson's disease treated with carbidopa/levodopa. INBRIJA is not to be used by patients who take or have taken a nonselective monoamine oxidase inhibitor
Acorda Therapeutics, Inc. (NASDAQ:ACOR) today announced a webcast/conference call in conjunction with its fourth quarter and year end 2023 update and financial results for Monday, April 1 at 4:30 p.m. ET. To participate in the webcast, please use the following registration link: https://events.q4inc.com/attendee/373031481 If you register for the webcast, you will have the opportunity to submit a written question for the Q&A portion of the presentation. After you have registered, you will receive a confirmation email with the webcast details. On the day of the webcast, you will receive an email 2 hours prior to the start of the webcast with the link to join. The presentation will be
INBRIJA® (levodopa inhalation powder) Q3 2023 U.S. net revenue of $8.1 million; 4% increase over Q3 2022 AMPYRA® (dalfampridine) Q3 2023 net revenue of $15.7 million; 26% decrease over Q3 2022 INBRIJA ex-U.S. revenue of $1.4 million; FAMPYRA royalties of $2.5 million Biopas Laboratories files for approval of INBRIJA in six Latin American countries Acorda Therapeutics, Inc. (NASDAQ:ACOR) today provided a business update and reported its financial results for the third quarter ended September 30, 2023. "We were pleased to see a 32% increase in new INBRIJA prescription requests in Q3 2023 over Q3 2022. New prescription requests have increased by 38% in the first three quarters o
Acorda Therapeutics, Inc. (NASDAQ:ACOR) will host a webcast/conference call in conjunction with its third quarter 2023 update and financial results on Monday, November 13 at 4:30 p.m. ET. To participate in the Webcast, please use the following registration link: https://events.q4inc.com/attendee/728181174 If you register for the Webcast, you will have the opportunity to submit a written question for the Q&A portion of the presentation. After you have registered, you will receive a confirmation email with the Webcast details. On the day of the Webcast, you will receive an email 2 hours prior to the start of the Webcast with the link to join. The presentation will be available on the
INBRIJA® (levodopa inhalation powder) Q2 2023 U.S. net revenue of $8.3 million, a 12% increase from Q2 2022; ex-U.S. net revenue of $0.8 million New INBRIJA prescription request forms increased 42% in 1H 2023 over 2022 AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg Q2 2023 net revenue of $16.9 million, a 7% decrease from Q2 2022; FAMPYRA royalty revenue of $2.9 million 2023 INBRIJA U.S. net revenue, adjusted operating expenses, and year-end cash guidance revised Company does not expect to be cash flow neutral in 2023 Nasdaq compliance regained after 1-for-20 reverse split Acorda Therapeutics, Inc. (NASDAQ:ACOR) today provided a business update and reported its fi
Acorda Therapeutics, Inc. (NASDAQ:ACOR) will host a webcast/conference call in conjunction with its second quarter 2023 update and financial results on Tuesday, August 8 at 4:30 p.m. ET. To participate in the Webcast, please use the following registration link: https://events.q4inc.com/attendee/268055678 If you register for the Webcast, you will have the opportunity to submit a written question for the Q&A portion of the presentation. After you have registered, you will receive a confirmation email with the Webcast details. On the day of the Webcast, you will receive an email 2 hours prior to the start of the Webcast with the link to join. The presentation will be available on the I
INBRIJA® (levodopa inhalation powder) Q1 2023 U.S. net revenue of $5.6 million, a 52% increase from Q1 2022; ex-U.S. net revenue of $0.5 million AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg Q1 2023 net revenue of $12.6 million, a 15% decrease from Q1 2022; FAMPYRA royalty revenue of $2.9 million 2023 financial guidance reaffirmed Agreement with Chance Pharmaceuticals to commercialize INBRIJA in China Tom Burns, Chief Financial Officer of XOMA, to be candidate for Board of Directors at 2023 Annual Meeting of Stockholders; Jeff Randall to rotate off the Board Acorda Therapeutics, Inc. (NASDAQ:ACOR) today provided a business update and reported its financial results
Acorda Therapeutics, Inc. (NASDAQ:ACOR) will host a webcast/conference call in conjunction with its first quarter 2023 update and financial results on Thursday, May 11 at 4:30 p.m. ET. To participate in the Webcast, please use the following registration link: https://events.q4inc.com/attendee/539980595 If you register for the Webcast, you will have the opportunity to submit a written question for the Q&A portion of the presentation. After you have registered, you will receive a confirmation email with the Webcast details. On the day of the Webcast, you will receive an email 2 hours prior to the start of the Webcast with the link to join. The presentation will be available on the Inv
INBRIJA® (levodopa inhalation powder) 2022 U.S. net revenue of $28.0MM and ex-U.S. net revenue of $2.9MM; Q4 2022 U.S. net revenue of $9.0MM AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg 2022 net revenue of $72.9MM and FAMPYRA royalty revenue of $11.7MM; Q4 2022 AMPYRA net revenue of $18.8MM Achieved AMPYRA and INBRIJA U.S. net revenue, cash, and adjusted OPEX1 guidance for 2022 Full-year 2023 guidance and long-term outlook provided Nasdaq Hearings Panel grants extension until June 20, 2023 Acorda Therapeutics, Inc. (NASDAQ:ACOR) today reported its financial results for the fourth quarter and full year ended December 31, 2022. "Acorda's operating and financial performa
Acorda Therapeutics, Inc. (NASDAQ:ACOR) will host a webcast/conference call in conjunction with its fourth quarter and year end 2022 update and financial results on Thursday, March 9 at 8:30 a.m. ET. To participate in the Webcast, please use the following registration link: https://events.q4inc.com/attendee/932428600 If you register for the Webcast, you will have the opportunity to submit a written question for the Q&A portion of the presentation. After you have registered, you will receive a confirmation email with the Webcast details. On the day of the Webcast, you will receive an email 2 hours prior to the start of the Webcast with the link to join. The presentation will be availabl
SC 13D/A - Acorda Therapeutics, Inc. (0001008848) (Subject)
SC 13D/A - ACORDA THERAPEUTICS INC (0001008848) (Subject)
SC 13G/A - ACORDA THERAPEUTICS INC (0001008848) (Subject)
SC 13G/A - ACORDA THERAPEUTICS INC (0001008848) (Subject)
SC 13D/A - ACORDA THERAPEUTICS INC (0001008848) (Subject)
SC 13G - ACORDA THERAPEUTICS INC (0001008848) (Subject)
SC 13D - ACORDA THERAPEUTICS INC (0001008848) (Subject)
SC 13G/A - ACORDA THERAPEUTICS INC (0001008848) (Subject)
SC 13G/A - ACORDA THERAPEUTICS INC (0001008848) (Subject)
SC 13G/A - ACORDA THERAPEUTICS INC (0001008848) (Subject)
Acorda Therapeutics, Inc. today announced that its common stock is no longer listed on the Nasdaq Stock Market. The delisting is a result of the Company's failure to demonstrate compliance with Nasdaq Listing Rules 5101, 5110(b), and IM-5101-1 as a result of the Company's commencement of Chapter 11 proceedings and Nasdaq Listing Rule 5450(b)(1)(A) for failure to maintain stockholders' equity of at least $10 million. Trading in the Company's common stock on the Nasdaq exchange was suspended on April 12, 2024. The Company's common stock is quoted on the OTC Pink® Open Market platform operated by OTC Markets Group Inc. since April 12, 2024 under the "ACORQ" ticker symbol. About Acorda Therap
Acorda Therapeutics, Inc. (NASDAQ:ACOR) announced that Nasdaq Stock Market ("Nasdaq") today notified the Company that it will suspend trading in and delist the Company's common stock, effective with the opening of business on April 12, 2024. The notice follows the Company's April 1, 2024 announcement that it has reached an agreement with Merz Therapeutics to acquire substantially all of the assets of the Company. In connection with that announcement, Acorda and certain of its affiliates filed voluntary petitions to commence Chapter 11 proceedings in the U.S. Bankruptcy Court for the Southern District of New York. Nasdaq commenced proceedings to delist the Company's common stock, based on th
Acorda Files for Voluntary Chapter 11 Protection to Facilitate Orderly Sale Acorda Enters into a Restructuring Support Agreement with over 90% of the Secured Convertible Noteholders Patient Access to INBRIJA® (levodopa inhalation powder) and AMPYRA® (dalfampridine) to Continue Uninterrupted Acorda Therapeutics, Inc. (NASDAQ:ACOR) ("Acorda" or "the Company") today announced that it has entered into an asset purchase agreement with Merz Therapeutics to purchase substantially all of the assets of Acorda, including the rights to INBRIJA, AMPYRA, and FAMPYRA for $185 million. Merz Therapeutics, a leader in the field of neurotoxins, is a business of the global family-owned company Merz, hea
Acorda Therapeutics, Inc. (NASDAQ:ACOR) today announced that it will no longer hold its fourth quarter and year end 2023 earnings conference call originally scheduled for Monday, April 1 at 4:30 p.m. ET. The Company does expect to timely file its Annual Report on Form 10-K for the period ended December 31, 2023. About Acorda Therapeutics Acorda Therapeutics develops therapies to restore function and improve the lives of people with neurological disorders. INBRIJA® is approved for intermittent treatment of OFF episodes in adults with Parkinson's disease treated with carbidopa/levodopa. INBRIJA is not to be used by patients who take or have taken a nonselective monoamine oxidase inhibitor
Acorda Therapeutics, Inc. (NASDAQ:ACOR) today announced a webcast/conference call in conjunction with its fourth quarter and year end 2023 update and financial results for Monday, April 1 at 4:30 p.m. ET. To participate in the webcast, please use the following registration link: https://events.q4inc.com/attendee/373031481 If you register for the webcast, you will have the opportunity to submit a written question for the Q&A portion of the presentation. After you have registered, you will receive a confirmation email with the webcast details. On the day of the webcast, you will receive an email 2 hours prior to the start of the webcast with the link to join. The presentation will be
Acorda Therapeutics, Inc. (NASDAQ:ACOR) today announced it will regain global commercialization rights to FAMPYRA® (fampridine) following a decision by Biogen to terminate the license and collaboration agreement between the companies, effective January 1, 2025. FAMPYRA is indicated in the European Union and other territories throughout the world for the improvement of walking in adults with multiple sclerosis (MS) with walking disability. Acorda markets the medication as AMPYRA® (dalfampridine) in the United States. Acorda and Biogen are working together toward a transition for Acorda to commercialize and supply FAMPYRA for the great majority of people with MS outside the United States cu
INBRIJA® (levodopa inhalation powder) Q3 2023 U.S. net revenue of $8.1 million; 4% increase over Q3 2022 AMPYRA® (dalfampridine) Q3 2023 net revenue of $15.7 million; 26% decrease over Q3 2022 INBRIJA ex-U.S. revenue of $1.4 million; FAMPYRA royalties of $2.5 million Biopas Laboratories files for approval of INBRIJA in six Latin American countries Acorda Therapeutics, Inc. (NASDAQ:ACOR) today provided a business update and reported its financial results for the third quarter ended September 30, 2023. "We were pleased to see a 32% increase in new INBRIJA prescription requests in Q3 2023 over Q3 2022. New prescription requests have increased by 38% in the first three quarters o
Acorda Therapeutics, Inc. (NASDAQ:ACOR) will host a webcast/conference call in conjunction with its third quarter 2023 update and financial results on Monday, November 13 at 4:30 p.m. ET. To participate in the Webcast, please use the following registration link: https://events.q4inc.com/attendee/728181174 If you register for the Webcast, you will have the opportunity to submit a written question for the Q&A portion of the presentation. After you have registered, you will receive a confirmation email with the Webcast details. On the day of the Webcast, you will receive an email 2 hours prior to the start of the Webcast with the link to join. The presentation will be available on the
Up to five approvals expected in 2024 Additional filings expected in Chile in late 2023 and in Mexico and Brazil in 2024 Acorda Therapeutics, Inc. (NASDAQ:ACOR) today announced the submission of new regulatory filings for the approval of INBRIJA® (levodopa inhalation powder) in six countries in Latin America by its partner Biopas Laboratories (Biopas). INBRIJA is indicated in the United States for the intermittent treatment of OFF episodes in adult patients with Parkinson's disease (PD) treated with carbidopa/levodopa. Biopas has submitted for marketing approval of INBRIJA in Argentina, Colombia, Costa Rica, Ecuador, Panama and Peru. It expects to submit additional regulatory filings
INBRIJA® (levodopa inhalation powder) Q2 2023 U.S. net revenue of $8.3 million, a 12% increase from Q2 2022; ex-U.S. net revenue of $0.8 million New INBRIJA prescription request forms increased 42% in 1H 2023 over 2022 AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg Q2 2023 net revenue of $16.9 million, a 7% decrease from Q2 2022; FAMPYRA royalty revenue of $2.9 million 2023 INBRIJA U.S. net revenue, adjusted operating expenses, and year-end cash guidance revised Company does not expect to be cash flow neutral in 2023 Nasdaq compliance regained after 1-for-20 reverse split Acorda Therapeutics, Inc. (NASDAQ:ACOR) today provided a business update and reported its fi
10-Q - Acorda Therapeutics, Inc. (0001008848) (Filer)
10-K/A - Acorda Therapeutics, Inc. (0001008848) (Filer)
8-K - Acorda Therapeutics, Inc. (0001008848) (Filer)
8-K - Acorda Therapeutics, Inc. (0001008848) (Filer)
8-K - Acorda Therapeutics, Inc. (0001008848) (Filer)
10-K - Acorda Therapeutics, Inc. (0001008848) (Filer)
8-K - Acorda Therapeutics, Inc. (0001008848) (Filer)
8-K - Acorda Therapeutics, Inc. (0001008848) (Filer)
8-K - Acorda Therapeutics, Inc. (0001008848) (Filer)
10-Q - Acorda Therapeutics, Inc. (0001008848) (Filer)
Acorda Therapeutics, Inc. (NASDAQ:ACOR) today announced that Lauren Sabella, Chief Operating Officer, will resign from the Company effective September 30, 2022. Ms. Sabella will be working in a strategic advisory role for early-stage biotechnology companies. "We are grateful for Lauren's thirteen years of contributions as a member of Acorda's executive leadership team. Initially, she and her team led the commercial launch of AMPYRA, a novel treatment for multiple sclerosis. The tremendous success of that product allowed Acorda to invest in additional clinical development programs, including INBRIJA for Parkinson's disease," said Ron Cohen, M.D., Acorda's President and CEO. "Lauren has been